Albert Bourla adds 25 phantom stock units; holdings 731,111
Rhea-AI Filing Summary
Pfizer (PFE) reported an insider transaction by Chairman & CEO and Director Albert Bourla on 10/15/2025. The filing shows the acquisition of 25 phantom stock units under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan at a price of $24.39 per unit. Following this transaction, Bourla’s derivative holdings total 731,111 phantom stock units, held directly. Each unit represents one phantom share of common stock and will be settled in cash after separation from service; units may be transferred into an alternative investment account at any time.
Positive
- None.
Negative
- None.
Insights
Small cash-settled award; administrative and non-dilutive.
Albert Bourla reported acquiring 25 phantom stock units at $24.39 on 10/15/2025, bringing total derivative holdings to 731,111 units. These units are part of a deferred compensation plan.
Because the units are settled in cash after separation, they do not involve share issuance and are typically non-dilutive to common shareholders. The reported quantity is small relative to outstanding equity.
The mechanics and timing are defined by plan terms; actual impact depends on future service and separation events as disclosed in subsequent filings.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Phantom Stock Units SSP | 25 | $24.39 | $609.75 |
Footnotes (2)
- F1. Each unit represents one phantom share of common stock.
- F2. These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.
AI-generated analysis. How Rhea-AI works. Not financial advice.